According to a recent LinkedIn post from M Ventures, portfolio company Lightcast has closed a $27 million financing round to support commercialization of its Envisia single-cell analysis platform. The round was led by ARCH Venture Partners with participation from M Ventures, Illumina Ventures, +ND Capital, Longwall Ventures, and OMX Ventures, and is portrayed as a significant milestone for Lightcast.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that Lightcast plans a full commercial release of the Envisia benchtop platform in 2026 and intends to deepen collaborations with pharmaceutical and academic partners. It also notes goals to expand the company’s portfolio of single-cell functional assays and scale technical, manufacturing, and software capabilities, suggesting an acceleration toward broader market entry.
According to the post, Lightcast has also brought on industry veteran Brad Crutchfield, formerly chief commercial officer at 10x Genomics, as an advisor to its board of directors. His involvement may strengthen the company’s commercial strategy and go-to-market execution, which could be relevant for investors tracking how quickly the Envisia platform may gain adoption in research and therapeutic development workflows.
For M Ventures, participation in this round reinforces its exposure to advanced life sciences tools targeting antibody discovery, oncology therapeutics, and cell line development. If Lightcast successfully executes on its commercialization roadmap and establishes meaningful partnerships, the investment could enhance M Ventures’ positioning in the competitive single-cell analysis and biotech tools space over the medium term.